Nomura Holdings’s Theravance Biopharma TBPH Stock Holding History

Nomura Holdings’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-97,500	Closed	-$725K	–	2461
2021 Q3	$725K	Buy	+97,500	New	+$1.09M	﹤0.01%	1255

Other funds holding TBPH

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Nomura Holdings's TBPH Position: Q4 2021 in Review

Nomura Holdings sold out of Theravance Biopharma (TBPH) in Q4 2021, closing a stake of 352 shares — an estimated $3K sold.

Nomura Holdings first reported a position in TBPH in Q2 2014 and held it in 4 quarters. The position peaked at $3.56M in Q2 2019. 116 funds tracked by Wall St. Rank hold TBPH as of Q4 2021.

Nomura Holdings reported no remaining Theravance Biopharma position as of Q4 2021 after selling out during the quarter.
Nomura Holdings sold 352 Theravance Biopharma shares in Q4 2021, an estimated $3K.
Nomura Holdings first reported a position in Theravance Biopharma in Q2 2014 and held it in 4 quarters.
Nomura Holdings's Theravance Biopharma position peaked at $3.56M in Q2 2019.
116 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2021.

Based on Nomura Holdings's 13F filing for Q4 2021, filed 14 Feb 2022.